These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20017105)

  • 41. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids.
    Glotz D; Charpentier B; Abramovicz D; Lang P; Rostaing L; Rifle G; Vanrenterghem Y; Berthoux F; Bourbigot B; Delahousse M; Chalopin JM; Cassuto E; Lefrançois N
    Transplantation; 2010 Jun; 89(12):1511-7. PubMed ID: 20386144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial.
    Weir MR; Mulgaonkar S; Chan L; Shidban H; Waid TH; Preston D; Kalil RN; Pearson TC
    Kidney Int; 2011 Apr; 79(8):897-907. PubMed ID: 21191361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.
    Paoletti E; Ratto E; Bellino D; Marsano L; Cassottana P; Cannella G
    J Nephrol; 2012; 25(5):709-18. PubMed ID: 22038336
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [De novo hemolytic uremic syndrome in a kidney-pancreas recipient in the postoperative period].
    Gutiérrez de la Fuente C; Sola E; Alférez MJ; Navarro A; Cabello M; Burgos D; González Molina M
    Nefrologia; 2004; 24 Suppl 3():3-6. PubMed ID: 15219059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impairment of renal function after islet transplant alone or islet-after-kidney transplantation using a sirolimus/tacrolimus-based immunosuppressive regimen.
    Andres A; Toso C; Morel P; Demuylder-Mischler S; Bosco D; Baertschiger R; Pernin N; Bucher P; Majno PE; Bühler LH; Berney T
    Transpl Int; 2005 Nov; 18(11):1226-30. PubMed ID: 16221151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
    Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
    J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients.
    Hakeam HA; Al-Jedai AH; Raza SM; Hamawi K
    Ann Transplant; 2008; 13(2):46-53. PubMed ID: 18566560
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Apoptosis of tubular epithelial cells in preimplantation biopsies of kidney grafts with immediate, slow and delayed function.
    Krol R; Chudek J; Karkoszka H; Ziaja J; Kolonko A; Pawlicki J; Kajor M; Wiecek A; Cierpka L
    Ann Transplant; 2011; 16(3):17-22. PubMed ID: 21959505
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neutrophil Gelatinase Associated Lipocalin Is an Early and Accurate Biomarker of Graft Function and Tissue Regeneration in Kidney Transplantation from Extended Criteria Donors.
    Cantaluppi V; Dellepiane S; Tamagnone M; Medica D; Figliolini F; Messina M; Manzione AM; Gai M; Tognarelli G; Ranghino A; Dolla C; Ferrario S; Tetta C; Segoloni GP; Camussi G; Biancone L
    PLoS One; 2015; 10(6):e0129279. PubMed ID: 26125566
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
    Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Histological characteristics of Acute Tubular Injury during Delayed Graft Function predict renal function after renal transplantation.
    Pieters TT; Falke LL; Nguyen TQ; Verhaar MC; Florquin S; Bemelman FJ; Kers J; Vanhove T; Kuypers D; Goldschmeding R; Rookmaaker MB
    Physiol Rep; 2019 Mar; 7(5):e14000. PubMed ID: 30821122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased apoptosis and expression of FasL, Bax and caspase-3 in human lupus nephritis class II and IV.
    Cui JH; Qiao Q; Guo Y; Zhang YQ; Cheng H; He FR; Zhang J
    J Nephrol; 2012; 25(2):255-61. PubMed ID: 21725926
    [TBL] [Abstract][Full Text] [Related]  

  • 56. De novo everolimus-based therapy in renal transplant recipients: effect on proteinuria and renal prognosis.
    Loriga G; Ciccarese M; Pala PG; Satta RP; Fanelli V; Manca ML; Serra G; Dessole P; Cossu M
    Transplant Proc; 2010 May; 42(4):1297-302. PubMed ID: 20534285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tubular atrophy and low netrin-1 gene expression are associated with delayed kidney allograft function.
    Wohlfahrtova M; Brabcova I; Zelezny F; Balaz P; Janousek L; Honsova E; Lodererova A; Wohlfahrt P; Viklicky O
    Transplantation; 2014 Jan; 97(2):176-83. PubMed ID: 24092381
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Omi/HtrA2 protease is associated with tubular cell apoptosis and fibrosis induced by unilateral ureteral obstruction.
    Kim J; Kim DS; Park MJ; Cho HJ; Zervos AS; Bonventre JV; Park KM
    Am J Physiol Renal Physiol; 2010 Jun; 298(6):F1332-40. PubMed ID: 20219823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thrombotic microangiopathy in marginal kidneys after sirolimus use.
    Pellé G; Xu Y; Khoury N; Mougenot B; Rondeau E
    Am J Kidney Dis; 2005 Dec; 46(6):1124-8. PubMed ID: 16310579
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen.
    Sampaio EL; Pinheiro-Machado PG; Garcia R; Felipe CR; Park SI; Casarini DE; Moreira S; Franco MF; Tedesco-Silva H; Medina-Pestana JO
    Clin Transplant; 2008; 22(2):141-9. PubMed ID: 18339132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.